Abbott a yau ya ba da sanarwar cewa Hukumar Kula da Abinci da Magunguna ta Amurka (FDA) ta amince da faɗaɗa nuni ga Tsarin CardioMEMS ™ HF na kamfanin don tallafawa kulawar ƙarin mutanen da ke fama da gazawar zuciya. Tare da faɗaɗa nuni, ƙarin majinyatan Amurka miliyan 1.2 yanzu sun cancanci amfana daga ci gaba da sa ido tare da firikwensin CardioMEMS, wanda ke nuna haɓakar haɓakar yawan jama'a na yanzu. Na'urar firikwensin yana ba da tsarin faɗakarwa da wuri wanda ke baiwa likitoci damar kariya daga mummunan gazawar zuciya.
Fiye da 6.2 miliyan Amirkawa suna da ciwon zuciya2, tare da ganewar asali da aka kiyasta zai ninka sau biyu ta 3. Yayin da ciwon zuciya cuta ce mai tsanani, zaɓuɓɓukan likita kamar CardioMEMS na iya ba marasa lafiya da likitocin su damar fahimtar aiki don taimakawa wajen sarrafa ciwon zuciya kafin ta ci gaba zuwa mataki na gaba. . Na'urar firikwensin CardioMEMS na'ura ce mai girman takarda wacce, da zarar an sanya shi a cikin jijiyar huhu a lokacin hanya mafi ƙanƙanta, tana sa ido kan canje-canjen matsin lamba wanda ke nuna rashin gazawar zuciya. Na'urar firikwensin ba tare da waya ba yana watsa karatun matsa lamba na yau da kullun ga ƙungiyar majiyyata - ƙyale likitocin suyi canje-canjen jiyya don yaƙar ci gaba zuwa gazawar zuciya na gaba yayin ƙarfafa majiyyaci don sarrafa yanayin su daga kusan ko'ina.
An fara yarda da Tsarin CardioMEMS HF a cikin 2014 don amfani da su a cikin Ƙungiyar Zuciya ta New York (NYHA) Class III marasa lafiya na ciwon zuciya tare da asibiti na rashin ciwon zuciya a cikin shekarar da ta gabata. Sabuwar alamar ta ba da damar firikwensin CardioMEMS don amfani da mutanen da ke zaune tare da raunin zuciya na Class II da kuma marasa lafiya waɗanda ke yin gwajin jini wanda ke nuna matakan haɓakar ƙwayoyin halitta waɗanda aka sani da peptides na natriuretic, waɗanda ke nuna rashin gazawar zuciya.
Philip B. Adamson, MD, babban jami'in kula da lafiya na kasuwancin ciwon zuciya na Abbott ya ce "Rashin ciwon zuciya tsere ne da lokaci inda sau da yawa muna baya saboda marasa lafiya ba sa samun kulawa da wuri." "Wannan faɗaɗa nunin yana nufin likitocin na iya ba da ƙarin mutane masu raunin zuciya a matakin farko, suna ba da damar hana ƙarin wahala da yuwuwar guje wa ci gaban mataki na gaba wanda zai iya yin tasiri sosai ga ingancin rayuwar mutum."
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- The new indication allows the CardioMEMS sensor to be used by people living with Class II heart failure and for patients who undergo a blood test showing elevated levels of biomarkers known as natriuretic peptides, which indicate worsening heart failure.
- While heart failure is a chronic disease, medical options like CardioMEMS can provide patients and their doctors with actionable insights to help manage heart failure before it progresses to a later stage.
- The CardioMEMS HF System was initially approved in 2014 for use in New York Heart Association (NYHA) Class III heart failure patients with a prior heart failure hospitalization within the last year.
